Ardelyx, Inc. (ARDX): Capital Expenditures
$1.49M
Year ended 2025-12-31
$599.0K
Trailing 12 months to 2026-06-30
+200.5%
3-year compound annual growth
+35.7%
5-year compound annual growth
-8.1%
10-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.49M | +47.6% | 2026-02-19, From 2025-01-01 |
| 2024-12-31 | $1.01M | +193.9% | 2026-02-19, From 2024-01-01 |
| 2023-12-31 | $344.0K | +525.5% | 2026-02-19, From 2023-01-01 |
| 2022-12-31 | $55.0K | -97.1% | 2025-02-20, From 2022-01-01 |
| 2021-12-31 | $1.87M | +476.2% | 2024-02-22, From 2021-01-01 |
| 2020-12-31 | $324.0K | -0.3% | 2023-03-02, From 2020-01-01 |
| 2019-12-31 | $325.0K | +4.5% | 2022-02-28, From 2019-01-01 |
| 2018-12-31 | $311.0K | -86.8% | 2021-03-08, From 2018-01-01 |
| 2017-12-31 | $2.35M | -51.6% | 2020-03-06, From 2017-01-01 |
| 2016-12-31 | $4.87M | +40.9% | 2019-03-06, From 2016-01-01 |
| 2015-12-31 | $3.45M | +86.1% | 2018-03-14, From 2015-01-01 |
| 2014-12-31 | $1.86M | +567.6% | 2017-02-17, From 2014-01-01 |
| 2013-12-31 | $278.0K | +117.2% | 2016-03-04, From 2013-01-01 |
| 2012-12-31 | $128.0K | n/a | 2015-03-05, From 2012-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Ardelyx, Inc. (ARDX) | 2025-12-31 | $1.49M | +47.6% |
| Innoviva, Inc. (INVA) | 2025-12-31 | $1.13M | +318.9% |
| Sinovac Biotech Ltd (SVA) | 2025-12-31 | $48.92M | -49.0% |
| Arcutis Biotherapeutics, Inc. (ARQT) | 2025-12-31 | $686.0K | +379.7% |
| Zai Lab Ltd (ZLAB) | 2025-12-31 | $8.10M | +43.2% |
| MannKind Corp (MNKD) | 2025-12-31 | $4.57M | -52.9% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $6.48M | -40.9% |
| BridgeBio Pharma, Inc. (BBIO) | 2025-12-31 | $1.10M | +17.6% |
| Mirum Pharmaceuticals, Inc. (MIRM) | 2025-12-31 | $954.0K | -3.9% |
Compare ARDX, INVA, SVA, ARQT side by side · Screen every company in Pharmaceutical Preparations ↗